An experimental allergic asthma drug from Rigel Pharmaceuticals Inc. just struck out. The inhaled drug, called R-343, failed to hit the main and secondary goals of a 276-patient Phase II clinical study, and South San Francisco's Rigel (NASDAQ: RIGL) said it would no longer target allergic asthma patients with the drug...